PsychoGenics Secures $3 Million in Company Funding for Cutting-Edge Preclinical Research in CNS and Orphan Disorders

PsychoGenics, a leading preclinical contract research organization (CRO) specializing in central nervous system (CNS) and orphan disorders, is thrilled to announce the successful closing of a $3 million funding round. This investment will significantly bolster our efforts to refine and expand our cutting-edge disease models and comprehensive preclinical capabilities, all aimed at accelerating the discovery of next-generation treatments for patients battling severely disabling CNS and orphan disorders. With our mission centered on reducing the attrition rate in clinical development, this funding will allow us to enhance our innovative translational approach, providing customized solutions tailored to the unique needs of our partners in biopharmaceutical development. We pride ourselves on our ability to identify statistically relevant phenotypic changes that enable our clients to quantify the efficacy of their therapies before they reach the clinic, greatly increasing the chances of success. This capital raise will further augment our extensive portfolio, which includes highly predictive disease models and robust capabilities in behavioral testing, electrophysiology, and molecular biology. These advancements are critical as we continue to support vital research in areas like Alzheimer’s disease, Huntington’s disease, autism spectrum disorders, and numerous others. The funding not only exemplifies confidence in our expertise and the quality of our work but also strengthens our commitment to delivering superior clinical candidates to patients in need. We are excited for what the future holds as we leverage these resources to drive innovation and improve lives.